Information de reference pour ce titreAccession Number: | 00005083-200106010-00015.
|
Author: | Shariat, Shahrokh F.; Shalev, Moshe; Menesses-Diaz, Andres; Yi Kim, Isaac; Kattan, Michael W.; Wheeler, Thomas M.; Slawin, Kevin M.
|
Institution: | From the Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology, and Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX; and Departments of Urology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.
|
Title: | |
Source: | Journal of Clinical Oncology. 19(11):2856-2864, June 1, 2001.
|
Abstract: | Purpose: Elevated local and circulating levels of transforming growth factor beta1 (TGF-[beta]1) have been associated with prostate cancer invasion and metastasis. We tested the hypothesis that preoperative plasma TGF-[beta]1 levels would independently predict cancer stage and prognosis in patients who undergo radical prostatectomy.
Patients and Methods: The study group consisted of 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer (median follow-up, 53.8 months). Preoperative plasma levels of TGF-[beta]1 were measured and correlated with pathologic parameters and clinical outcomes. TGF-[beta]1 levels also were measured in 44 healthy men without cancer, in 19 men with prostate cancer metastatic to regional lymph nodes, and in 10 men with prostate cancer metastatic to bone.
Results: Plasma TGF-[beta]1 levels in patients with lymph node metastases (14.2 +/- 2.6 ng/mL) and bone metastases (15.5 +/- 2.4 ng/mL) were higher than those in radical prostatectomy patients (5.2 +/- 1.3 ng/mL) and healthy subjects (4.5 +/- 1.2 ng/mL) (P < .001). In a preoperative analysis, preoperative plasma TGF-[beta]1 level and biopsy Gleason sum both were predictors of organ-confined disease (P = .006 and P = .006, respectively) and PSA progression (P < .001 and P = .021, respectively). In a postoperative multivariate analysis, preoperative plasma TGF-[beta]1 level, pathologic Gleason sum, and surgical margin status were predictors of PSA progression (P = .020, P = .020, and P = .022, respectively). In patients who progressed, preoperative plasma TGF-[beta]1 levels were higher in those with presumed distant compared with local-only failure (P = .019).
Conclusion: Plasma TGF-[beta]1 levels are markedly elevated in men with prostate cancer metastatic to regional lymph nodes and bone. In men without clinical or pathologic evidence of metastases, the preoperative plasma TGF-[beta]1 level is a strong predictor of biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.
(C) 2001 American Society of Clinical Oncology
|
References: | 1. Newcomer LM, Stanford JL, Blumenstein BA, et al: Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994. J Urol 158: 1427-1430, 1997
2. Merrill RM, Stephenson RA: Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 163: 503-510, 2000
3. Pound CR, Partin AW, Epstein JI, et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 24: 395-406, 1997
4. Oesterling JE, Martin SK, Bergstralh EJ, et al: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60, 1993
5. Engeler CE, Wasserman NF, Zhang G: Preoperative assessment of prostatic carcinoma by computerized tomography: Weaknesses and new perspectives. Urology 40: 346-350, 1992
6. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277: 1445-1451, 1997
7. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771, 1998
8. Morton DM, Barrack ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602, 1995
9. Matuo Y, Nishi N, Takasuka H, et al: Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochem Biophys Res Commun 166: 840-847, 1990
10. Steiner MS, Barrack ER: Transforming growth factor-beta 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 6: 15-25, 1992
11. Eastham JA, Truong LD, Rogers E, et al: Transforming growth factor-beta 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628-635, 1995
12. Truong LD, Kadmon D, McCune BK, et al: Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum Pathol 24: 4-9, 1993
13. Thompson TC, Truong LD, Timme TL, et al: Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 16H: 54-61, 1992
14. Shariat S, Menesses A, Kim I, et al: Tissue expression of transforming growth factor beta1 and its receptors: Correlation with pathologic parameters and progression in patients undergoing radical prostatectomy. 9th Annual Oncology Research Seminar, The Methodist Hospital and Baylor College of Medicine, Houston, TX, August 6, 2000
15. Wakefield LM, Letterio JJ, Chen T, et al: Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1: 129-136, 1995
16. Kong F, Jirtle RL, Huang DH, et al: Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86: 1712-1719, 1999
17. Shirai Y, Kawata S, Tamura S, et al: Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma: Comparison with chronic liver diseases. Cancer 73: 2275-2279, 1994
18. Eder IE, Stenzl A, Hobisch A, et al: Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol 156: 953-957, 1996
19. Junker U, Knoefel B, Nuske K, et al: Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 8: 794-798, 1996
20. Ivanovic V, Melman A, Davis-Joseph B, et al: Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1: 282-284, 1995 (letter)
21. Adler HL, McCurdy MA, Kattan MW, et al: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187, 1999
22. Kakehi Y, Oka H, Mitsumori K, et al: Elevation of serum transforming growth factor beta 1 level in patients with metastatic prostate cancer. Urol Oncol 2: 131-135, 1996
23. Wolff JM, Fandel TH, Borchers H, et al: Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases. Anticancer Res 19: 2657-2659, 1999
24. Perry KT, Anthony CT, Case T, et al: Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49: 151-155, 1997
25. Smith DS, Catalona WJ, Herschman JD: Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276: 1309-1315, 1996
26. Wheeler TM, Lebovitz RM: Fresh tissue harvest for research from prostatectomy specimens. Prostate 25: 274-279, 1994
27. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031-2040, 1993
28. Maru N, Utsunomiya T, Bergamaschi F, et al: The influence of pathological parameters of positive surgical margins on prognosis in patients undergoing radical prostatectomy. J Urol 161: 1280A, 1999 (abstr)
29. Epstein JI, Pound CR, Partin AW, et al: Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 160: 97-101, 1998
30. Tefilli MV, Gheiler EL, Tiguert R, et al: Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 160: 802-806, 1998
31. Epstein JI, Partin AW, Potter SR, et al: Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathologic parameters. Urology 56: 283-288, 2000
32. Eastham J, Scardino PT: Radical prostatectomy for clinical stage T1 and T2 prostate cancer, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Philadelpha, PA: Lippincott Williams & Wilkins, 2000, pp 722-7386
33. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 160: 2428-2434, 1998
34. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 152: 1831-1836, 1994
35. Kattan MW, Stapleton AM, Wheeler TM, et al: Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79: 528-537, 1997
36. Wheeler TM: Anatomic considerations in carcinoma of the prostate. Urol Clin North Am 16: 623-634, 1989
37. Ohori M, Wheeler TM, Kattan MW, et al: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824, 1995
38. Jones EC: Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 144: 89-93, 1990
39. Epstein JI, Partin AW, Sauvageot J, et al: Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20: 286-292, 1996
40. Leventis A, Shariat S, Kattan M, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19: 1030-1039, 2001
41. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999
42. Farkas A, Schneider D, Perrotti M, et al: National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 52: 444-449, 1998
43. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993
44. Wheeler TM, Dillioglugil O, Kattan MW, et al: Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 29: 856-862, 1998
45. Yao SL, Lu-Yao G: Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. Natl Cancer Inst 91: 1950-1956, 1999.
46. Potosky AL, Warren JL: Radical prostatectomy: Does higher volume lead to better quality? J Natl Cancer Inst 91: 1906-1907, 1999 (editorial)
47. Noguchi M, Stamey TA, McNeal JE, et al: Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol 164: 1596-1600, 2000
48. Stamey TA: Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 47: 631-634, 2001
49. Roberts AB, Sporn MB, Assoian RK, et al: Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83: 4167-4171, 1986
50. Lange PH, Vessella RL: Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17: 331-336, 1998
51. Melchior SW, Corey E, Ellis WJ, et al: Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 3: 249-256, 1997
52. Van Nguyen C, Song W, Scardino PT, et al: RT-PCR for PSA and hK2: Implications for staging and patient management in men undergoing radical prostatectomy. J Urol 159: 1114A, 1998 (abstr)
53. Akhurst RJ, Balmain A: Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol
|
Language: | English.
|
Document Type: | ORIGINAL REPORTS: Genitourinary.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0732-183X
|
NLM Journal Code: | jco, 8309333
|
Annotation(s) | |
|
|